天然物由来の有望なABL2阻害剤としての生物活性フィトコンスティテュエントの同定:バーチャルスクリーニングおよび分子動力学シミュレーションを用いた研究
Afnan Elayyan Mousa Elayyan1, Abdelbaset Mohamed Elasbali2, Marwah Ayed Meshhin Alanazi3
1Department of Clinical Laboratory, College of Applied Sciences-Qurayyat, Jouf University, 72388, Sakaka, Saudi Arabia.
Abstract:
ABL proto-oncogene 2 (ABL2) is an essential nonreceptor tyrosine kinase that regulates cytoskeletal dynamics, cell adhesion, and migration. ABL2 is dysregulated in multiple cancers and represents a promising therapeutic target. However, currently available tyrosine kinase inhibitors are limited by drug resistance and off-target effects. In this study, a structure-based virtual screening approach was performed to identify bioactive phytoconstituents with potential ABL2 inhibitory activity. An initial virtual screening of 11,908 natural compounds from the IMPPAT-2 library was conducted using molecular docking, and the best hits were subsequently filtered based on physicochemical and pharmacokinetic profiles. The top two compounds, Pachyrrhizin and Lupinisoflavone K, showed appreciable binding affinity with appropriate pharmacokinetic properties. Molecular dynamics simulations confirmed stable interactions within the ABL2 binding pocket, supported by hydrogen bonding throughout the simulation, suggesting constant binding of Pachyrrhizin and Lupinisoflavone K with ABL2. The conformational dynamics of these protein-ligand complexes were further confirmed by principal component analysis and free-energy landscape analysis. Overall, the findings suggest that Pachyrrhizin and Lupinisoflavone K may serve as potential ABL2 inhibitors, warranting further in vitro and in vivo validation.
さらに関連する動画
10:25Screening Traditional Chinese Medicine Compounds for Inhibiting UCHL3 Activity Based on Molecular Docking and Deubiquitinating Enzyme Probe Technology
Published on: November 22, 2024
10:29Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
